Your session is about to expire
← Back to Search
Intranasal ketamine for Depression
Study Summary
This trial will study the effects of ketamine on patients with depression who have or have not recently abused alcohol.
- Depression
- Suicidal Thoughts
- Alcoholism
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 33 Patients • NCT03539887Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are they looking for more test subjects at the moment?
"Yes, this is an ongoing trial that is looking for 50 participants at a single site, according to the latest update on clinicaltrials.gov from 7/9/2021."
Who meets the standards to be included in this experiment?
"This trial is looking for 50 patients that suffer from depression and are aged between 21 and 60. The most crucial requirements for candidates are as follows: They must have an SSI score over 4 (first five items), a Columbia scale (C-SSRS) score of 4 or 5, current suicidal ideation and depressive symptoms, a DSM-IV-TR depressive episode (also MADRS greater than or equal to 12), and a Young Mania Rating Scale (YMRS) score lower than 8. In addition, the patient must have a lifetime history of suicide attempt but not be taking any medication in the last 24 hours."
Are there any dangers to using ketamine as a nasal spray?
"There is evidence from earlier trials to support the safety of intranasal ketamine, which Power rates as a 3."
Is this study only available to octogenarians?
"The age limit for this study is 60 years old, with a minimum age of 21."
How many individuals are taking part in this clinical trial?
"Yes, this is an ongoing clinical trial that has been recruiting since May 1st, 2018. The latest update was on July 9th, 2021 and the goal is to enroll 50 participants from a single site."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- The University of Texas Health Science Center at Houston: < 24 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger